Carboplatin
Orphan DrugFDA Approved
Description
Carboplatin is a second-generation platinum compound chemotherapy agent with a mechanism similar to cisplatin but with reduced nephrotoxicity and neurotoxicity. It is used in treatment protocols for rare thoracic malignancies including pulmonary blastoma, often in combination with other chemotherapeutic agents. The drug has orphan designation for several rare cancers.
Indications & Therapeutic Use
Ovarian cancer, lung cancer, pulmonary blastoma, germ cell tumors
Linked Diseases:
pulmonary blastoma
D018202
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Carboplatin
| Generic Name | Carboplatin |
| Brands | 1 brand available |
| Active Ingredient | Carboplatin |
| Drug Class | Ovarian cancer |
| Manufacturer | Bristol-Myers Squibb |
| Dosage Forms | IV infusion 10mg/mL |
| Medical Code | L01XA02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes